Additionally, the synergistic interaction between ONECUT2 and hypoxia has led to the investigation of an alternative therapeutic strategy involving the use of the hypoxia-activated prodrug TH-302, which reduces NEPC tumor growth in both xenograft and PDX (patient-derived xenografts) models [66]. The gene discussed is ONECUT2; the disease is neoplasm.